Cardiac MRI-guided iron-chelator treatment after a heart attack
Part of Heart & circulation clinical trials.
This Phase 2 trial tests whether giving deferiprone (an “iron-chelator,” meaning it helps remove excess iron) guided by cardiac MRI can improve outcomes after an acute anterior heart attack. It aims to study safety and benefit for people who can undergo MRI with contrast and meet specific heart, kidney, liver, and blood criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 79
- You recently had an anterior wall STEMI heart attack and got emergency angiogram with primary PCI (a procedure to open a blocked artery)
- You have not had a heart attack, stent/angioplasty (PCI), or bypass (CABG) in the past year
- Your heart’s pumping strength (LVEF) is 40% or higher
- You can safely get a cardiac MRI with contrast: no gadolinium/contrast allergy and no metal/other MRI safety issues
- Your kidneys and liver tests are safe (eGFR 30 or higher; ALT and AST not more than 2× the upper normal limit); also your blood counts are adequate (ANC 1.5 or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving IV ferric carboxymaltose can lower the risk of death and heart complications after a recent heart attack, and improve quality of life. It is for adults with low iron levels and specific heart/health risk factors identified soon after their heart attack.
This trial tests a new type of MRI with a special dye (ferumoxytol) to better find blood clots in the heart. It is for people who have a left ventricular aneurysm (a bulging area in the heart's main pumping chamber) or who had a heart procedure called percutaneous ventricular reconstruction about 6 months ago.
This study tests whether giving iron through a vein can improve quality of life in older adults who recently had a heart attack or unstable angina and also have low iron levels. If you qualify, you would receive either iron or a placebo (inactive substance) to see if iron helps you feel better and recover faster.
This trial compares two medicines (deferoxamine and colchicine) to see if they can prevent further brain damage after a spontaneous brain bleed (intracerebral hemorrhage). The goal is to improve recovery by reducing inflammation and iron-related damage.
This study tests whether a combination of intravenous (IV) iron and an SGLT2 inhibitor (a type of diabetes and heart failure medication) improves heart function and iron levels in people with heart failure and low iron. It may help strengthen your heart and improve your energy.
This trial studies deferoxamine, a medicine that targets iron-related injury, in people with an aneurysmal subarachnoid hemorrhage (a brain bleed caused by a burst aneurysm). It aims to improve neurologic recovery after the aneurysm is treated.
Hear when a new Acute Myocardial Infarction Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.